Robert Woods
Vermogen: 2 M $ op 31-05-2026
Vermogen: 2 M $ op 31-05-2026
Momenteel bekleedt R. Keith Woods de functie van Chief Operating Officer van argenx SE. In zijn vorige carrière bekleedde hij de positie van SVP-North American Operations bij Alexion Pharmaceuticals, Inc. en Vice President & Managing Director bij Alexion Pharma UK Ltd. (een dochteronderneming van Alexion Pharmaceuticals, Inc.). (een dochteronderneming van Alexion Pharmaceuticals, Inc.). Hij behaalde een bachelordiploma aan de Florida State University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-04-2026 | 48.034 ( 0,04% ) | 2 M $ | 31-05-2026 | |
| 09-06-2025 | 6.000 ( 0,01% ) | 25 860 $ | 31-05-2026 | |
-.--% | 07-04-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| 20-05-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Directeur/Bestuurslid | 06-12-2023 |
| SCHOLAR ROCK HOLDING CORPORATION | Operationeel Directeur | 27-04-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 22-08-2025 |
| ROCKET PHARMACEUTICALS, INC. | Operationeel Directeur | 18-06-2025 |
| ARGENX SE | Corporate Officer/Principal | 01-06-2023 |
Alexion Pharma UK Ltd.
Alexion Pharma UK Ltd. Medical DistributorsDistribution Services Wholesales pharmaceuticals | Corporate Officer/Principal | - |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 8 |
|---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Florida State University
Florida State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
argenx SE
argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Scholar Rock Holding Corp.
Scholar Rock Holding Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focused on the discovery, development and delivery medicines for neuromuscular, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia | Health Technology |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Alexion Pharma UK Ltd.
Alexion Pharma UK Ltd. Medical DistributorsDistribution Services Wholesales pharmaceuticals | Distribution Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau